321 related articles for article (PubMed ID: 20309546)
21. A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.
Schwenkert M; Birkholz K; Schwemmlein M; Kellner C; Kügler M; Peipp M; Nettelbeck DM; Schuler-Thurner B; Schaft N; Dörrie J; Ferrone S; Kämpgen E; Fey GH
Melanoma Res; 2008 Apr; 18(2):73-84. PubMed ID: 18337643
[TBL] [Abstract][Full Text] [Related]
22. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
23. Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library.
Geiser M; Schultz D; Le Cardinal A; Voshol H; García-Echeverría C
Cancer Res; 1999 Feb; 59(4):905-10. PubMed ID: 10029083
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
25. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.
Krug C; Birkholz K; Paulus A; Schwenkert M; Schmidt P; Hoffmann N; Hombach A; Fey G; Abken H; Schuler G; Schuler-Thurner B; Dörrie J; Schaft N
Cancer Immunol Immunother; 2015 Dec; 64(12):1623-35. PubMed ID: 26515978
[TBL] [Abstract][Full Text] [Related]
26. One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics.
Chen W; Yang F; Wang C; Narula J; Pascua E; Ni I; Ding S; Deng X; Chu ML; Pham A; Jiang X; Lindquist KC; Doonan PJ; Van Blarcom T; Yeung YA; Chaparro-Riggers J
MAbs; 2021; 13(1):1871171. PubMed ID: 33557687
[TBL] [Abstract][Full Text] [Related]
27. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
Haas C; Krinner E; Brischwein K; Hoffmann P; Lutterbüse R; Schlereth B; Kufer P; Baeuerle PA
Immunobiology; 2009; 214(6):441-53. PubMed ID: 19157637
[TBL] [Abstract][Full Text] [Related]
28. Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Märkl F; Benmebarek MR; Keyl J; Cadilha BL; Geiger M; Karches C; Obeck H; Schwerdtfeger M; Michaelides S; Briukhovetska D; Stock S; Jobst J; Müller PJ; Majed L; Seifert M; Klüver AK; Lorenzini T; Grünmeier R; Thomas M; Gottschlich A; Klaus R; Marr C; von Bergwelt-Baildon M; Rothenfusser S; Levesque MP; Heppt MV; Endres S; Klein C; Kobold S
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37208128
[TBL] [Abstract][Full Text] [Related]
29. Generation and characterization of monospecific and bispecific hexavalent trimerbodies.
Blanco-Toribio A; Sainz-Pastor N; Álvarez-Cienfuegos A; Merino N; Cuesta ÁM; Sánchez-Martín D; Bonet J; Santos-Valle P; Sanz L; Oliva B; Blanco FJ; Álvarez-Vallina L
MAbs; 2013; 5(1):70-9. PubMed ID: 23221741
[TBL] [Abstract][Full Text] [Related]
30. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
31. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
Kuo SR; Wong L; Liu JS
Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
[TBL] [Abstract][Full Text] [Related]
32. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
33. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
34. Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.
de Bruyn M; Rybczynska AA; Wei Y; Schwenkert M; Fey GH; Dierckx RA; van Waarde A; Helfrich W; Bremer E
Mol Cancer; 2010 Nov; 9():301. PubMed ID: 21092273
[TBL] [Abstract][Full Text] [Related]
35. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
[TBL] [Abstract][Full Text] [Related]
36. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
37. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.
Reinhold U; Liu L; Lüdtke-Handjery HC; Heuser C; Hombach A; Wang X; Tilgen W; Ferrone S; Abken H
J Invest Dermatol; 1999 May; 112(5):744-50. PubMed ID: 10233766
[TBL] [Abstract][Full Text] [Related]
38. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1
Hong R; Zhou Y; Tian X; Wang L; Wu X
Int Immunopharmacol; 2018 Jan; 54():118-124. PubMed ID: 29128855
[TBL] [Abstract][Full Text] [Related]
39. Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study.
Pfosser A; Brandl M; Salih H; Grosse-Hovest L; Jung G
Int J Cancer; 1999 Feb; 80(4):612-6. PubMed ID: 9935165
[TBL] [Abstract][Full Text] [Related]
40. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]